Dr Reddy's to market three of Amgen's drugs in India

Indian drug major Dr Reddy's Laboratories (NYSE:RDY) has entered into a strategic collaboration with USA-based Amgen (Nasdaq: AMGN) – a leading independent biotechnology company – to market and distribute three Amgen drugs in India in the areas of oncology and cardiology.

Dr Reddy's shares on Thursday surged as much as 3.2% to hit a 52-week high of 4,326.5 rupees after the announcement. Analysts say the collaboration with Amgen may result in increased revenues for Dr Reddy's Laboratories.

Deal covers Kyprolis, Blincyto and Repatha

Under the terms of the collaboration, financial aspects of which were not disclosed, Dr Reddy’s will perform a full range of regulatory and commercial services to seek approval and launch Kyprolis (carfilzomib), Blincyto (blinatumomab) and Repatha (evolocumab) in India. The accord leverages the capabilities of both companies, combining three of Amgen’s innovative therapies with Dr Reddy’s deep understanding of patient and physician needs in India, the company said.